Hot Picks: Biotech stocks rally as M&A activity accelerates further
Biotech stocks outperformed the broader market this year as investors rotated into growth and as M&A activity picked up, according to a Wedbush interview on BNN Bloomberg. The report cites an $11 billion AbbVie deal for Apogee. Wedbush highlighted Kiniksa (Q revenue $214M; raised guidance), Monte Rosa (Phase 2 updates), and Scholar Rock (FDA PDUFA Sept. 30; revenue estimates $163M in 2027, $450M in 2028).
How this was made
The 30-second read
Why it matters
The article’s tradable elements are the named catalysts for the featured companies (commercial results/guidance for Kiniksa; Sept. 30 PDUFA for Scholar Rock) and a supportive sector backdrop from M&A activity.
Market read
Provides a catalyst calendar-style view for two featured biotech names and a sentiment tailwind from ongoing biotech M&A, but it is not a fresh primary disclosure beyond the cited recent quarter/guidance and the stated PDUFA date.
What to watch
No valuation, probability-of-success, or competitive landscape details are provided; traders may need to independently assess FDA/clinical risk and dilution/financing over the catalyst horizon.
Background
BNN Bloomberg interviews Wedbush’s Sahak Manuelian on biotech’s rebound, citing rotation into growth and an active M&A tape.
Ticker impact
Kiniksa is highlighted after reporting revenues north of $214M and raising full-year guidance, plus Phase 2/3 KPL-387 data expected H2 2026.
Moderate positive bias; likely volatility around any incremental pipeline updates leading into H2 2026.
The article provides concrete commercial performance (revenue growth) and a specific upcoming catalyst window (Phase 2/3 data in H2 2026), which can drive re-rating for small/mid-cap biotech.
Scholar Rock is discussed with an FDA review lead-candidate decision and a PDUFA date set for Sept. 30.
High event-driven volatility; direction depends on FDA outcome, with positive skew if market already prices favorable Phase 3 results.
The text specifies the regulatory decision timing (PDUFA Sept. 30) and cites positive Phase 3 data, both of which are direct trading drivers.
Market effects
Reinforces a positive read-through from accelerating biotech M&A and rotation back into growth/momentum small- and mid-cap therapeutics.
Primarily US small/mid-cap biotech sentiment; no explicit regional breakdown provided.
M&A and pipeline-catalyst framing is globally relevant for biotech risk appetite, but no cross-border deal specifics are provided.
Counterpoint
The piece is a 'Hot Picks' discussion; it may over-weight optimism around approvals/data windows while under-weighting binary regulatory/clinical failure risk.
Key entities
- companyKiniksa Pharmaceuticals
Commercial-stage biopharma with rilonacept (Arcalyst) licensed from Regeneron; discussed after reporting revenue growth and raised full-year guidance, plus KPL-387 Phase 2/3 data expected H2 2026.
- companyScholar Rock
SMA-focused biopharma; discussed with a lead candidate in FDA review and a PDUFA date set for Sept. 30.
- companyAbbVie
Mentioned as part of an M&A deal 'AbbVie for Apogee' used to illustrate the active takeover environment.
